KNSA // Kiniksa Pharmaceuticals International plc Class A

DES <GO> NASDAQ CIK 0001730430 ↗

Health Care • Biotechnology: Pharmaceutical Preparations

$97.56 ▲ +2.38 (+2.50%)

MKT CAP: $7.67B • VOL: 1.38M

52W L $37 52W H $98

ALTMAN Z

24.45 SAFE

PIOTROSKI

9 / 9

KNSA // ROARABLE RATING & 5-PILLAR RQD CONFIDENCE 02:00 EST DETERMINISTIC ENGINE

PRIOR: RQD 65/100 [C] (-1 PT) • UNCHANGED AS OF 2026-11-01

ROARABLE C

RQD CONFIDENCE

64 / 100 -1D

5 X 20-PT QUANT PILLARS

E 0 D 35 C 59 B 70 A 86+

Roarable Hold — Fair / Balanced Risk-Reward

01 MASSIVE / SEC XBRL

Forensic Fundamentals

15 / 20

SOLID

FCF +200% vs NI +200% • ROIC-WACC +0.1% • Z 24.45

02 OPRA GEX + SEC 13F

Whale & Options Flow

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

03 SEC FORM 4 (90D)

Insider Conviction

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

04 FRED 90D r-MATRIX

Macro Regime Fit

14 / 20

SOLID

TAILWIND • r(10Y)=+0.00 (+23bp) • r(OAS)=+0.00

05 10-K REDLINE AUDIT

Forensic 10-K Risk

13 / 20

SOLID

20 BASE - 7 DEDUCT • 0 CRIT / 0 MED • STABLE

ALERT

Why did KNSA's Whale & Options Flow & Insider Conviction sub-score just flash a warning? Enter your email to unlock the full 5-Pillar Rating Breakdown + get instant alerts whenever KNSA is Upgraded or Downgraded.

SIG <GO> CROSS-FEED TRIANGULATION // PROPRIETARY ANOMALY ENGINE (1 ACTIVE ON KNSA)

STAGE 2 DETERMINISTIC Z-SCORE + STAGE 3 GEEK DESK BRIEF ALL MARKET ANOMALIES <SIG>

▼ BEARISH // F-RATED EARNINGS MIRAGE // ACCRUAL WATCHSIFTER 02 // ACCRUAL & RECEIVABLES FORENSICS

SEVERITY: 81/100 Z-SCORE: +2.24σ

KNSA Accounting Gap: Net Income (+220%) Outpaced OCF (+220%) With +83.9% Working-Capital Build

CASH CONVERSION GAP

+0.0% (NI vs OCF)

RECEIVABLES / WC BLOAT

+83.9% VS REV

60D C-SUITE FORM 4 SALES

0 OPEN-MKT DUMPS

[GEEK DESK FORENSIC NOTE // SEC XBRL × FORM 4 CROSS-CHECK]

SEC EDGAR XBRL CompanyFacts10-K/10-Q Working Capital ScheduleSEC Form 4 Executive Sales

SEC EDGAR XBRL triangulation on Kiniksa Pharmaceuticals International plc Class A (KNSA) exposes a +0.0% Cash Conversion Gap as YoY Net Income growth (+220.0%) diverged from Operating Cash Flow growth (+220.0%). Non-cash current assets and receivables expanded +83.9% relative to top-line revenue growth. Monitor upcoming 10-Q cash realization closely for accrual mean-reversion.

KNSA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +71.51%▲ ASCENDING CHANNEL

2026-10-30O $97.40H $98.48L $91.25C $92.24VOL 1.32M

RES: $111.7SUP: $71.28SMA50: $79.16SMA200: $60.21

KNSA // INSTITUTIONAL BULL VS. BEAR FORENSIC DEBATE

UNDERWEIGHT CONVICTION: 42/100

BEAR 0

100 BULL

Kiniksa Pharmaceuticals International plc Class A (KNSA) exhibits 88.5% gross margins and 9.9% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 95.0x enterprise multiple and 7.3% implied options volatility.

▲ INSTITUTIONAL BULL THESIS (LONG)

01. Operating Leverage & Capital Efficiency Moat

Sustained 88.5% gross profitability converts into 11.4% operating margin and 9.9% ROIC, outpacing sector cost of capital.

ROIC: 9.9% // GM: 88.5%

02. Top-Line Expansion & Cash Conversion

YoY revenue trajectory of +60.1% paired with 1.78% free cash flow yield supports self-funded R&D and capital return.

REV YOY: +60.1% // FCF YLD: 1.78%

03. Balance Sheet Solvency & Forensic Quality

Altman Z-Score of 24.45 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.

ALTMAN Z: 24.45 // F-SCORE: 9/9

▼ INSTITUTIONAL BEAR THESIS (SHORT / RISK)

01. Multiple Compression & Duration Sensitivity

Trading at 129.9x trailing P/E (109.1x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.

P/E: 129.9x // EV/EBITDA: 95.0x

02. Options Skew & Event Volatility Risk

Options market prices a ±7.3% implied move with a 0.72 put/call ratio around $96.00 max pain.

IMPL MOVE: ±7.3% // P/C: 0.72

03. Competitive Margin & CapEx Cycle Pressure

Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 8.7% net margins.

NET MARGIN: 8.7% // D/E: 0.15x

KEY CATALYST // Upcoming 10-Q/10-K XBRL margin progression, guidance revision vs 109.1x forward consensus, and institutional 13F positioning.

MACRO REGIME // Monitor US 10Y Real Yields (DFII10) and High-Yield Credit Spreads (OAS) for beta-adjusted multiple impact (Beta 1.11).

FORM 4 & 13F FLOW OPEN OWN <GO>

FILER	SIDE	$ VALUE
INSPECT FULL OWNERSHIP LEDGER IN OWN <GO>

UNUSUAL OPTIONS TAPE OPEN OPT <GO>

STRIKE / EXP	TYPE	PREMIUM
INSPECT GEX & CHAIN IN OPT <GO>

KEY VALUATION & PROFITABILITY RATIOS XBRL FA <GO>

TRAILING P/E 129.9x

FORWARD P/E 109.1x

EV / EBITDA 95.0x

FCF YIELD 1.78%

GROSS MARGIN 88.5%

OPERATING MARGIN 11.4%

NET MARGIN 8.7%

ROIC % 9.9%

REV GROWTH YOY +60.1%

DILUTED EPS TTM $0.75

DEBT / EQUITY 0.15x

DIVIDEND YIELD 0.00%

RSI-14 MOMENTUM 63.0

5Y EQUITY BETA 1.11

FRED MACRO SENSITIVITY (PEARSON r) ECST <GO>

MACRO CORRELATION CALIBRATION ACTIVE BELOW.

FRED MACRO REGIME STRESS-TEST SIMULATOR // KNSAPEARSON R VARIANCE ENGINE

01 // SELECT FEDERAL RESERVE & CREDIT SHOCK SCENARIO

02 // POSITION NOTIONAL EXPOSURE

HEADLINE STRESS SCORE

75/100SEVERE DRAWDOWN PRESSURE

PRIMARY FACTOR EXPOSURE

DFII10 // -0.61 r

Latest: 2.08%

EST. DIRECTIONAL MOVE

-8.50%

Implied Px: $89.27

EST. DOLLAR VARIANCE

-$4,248

On $50,000 Notional

[LOCKED // MULTI-FACTOR DRAWDOWN HEDGE & MACRO TRIGGER ALERT]

Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for KNSA & activate live FRED threshold breach alerts.

HEAD-TO-HEAD PEER COMPARISONS COMP <GO>

KNSA VS LLY

MARGINS ROIC VALUATION

KNSA VS JNJ

MARGINS ROIC VALUATION

KNSA VS ABBV

MARGINS ROIC VALUATION

KNSA VS UNH

MARGINS ROIC VALUATION